Results 161 to 170 of about 212,225 (290)

TRIM40 Drives Pathological Cardiac Hypertrophy and Heart Failure via Ubiquitination of PKN2

open access: yesAdvanced Science, EarlyView.
This study identifies the E3 ligase TRIM40 as a key driver of pathological cardiac hypertrophy. TRIM40 binds PKN2 via its B‐box domain and, through its C29‐dependent catalytic activity, mediates K63‐linked ubiquitination of PKN2. This modification enhances PKN2 phosphorylation at Ser815, thereby driving hypertrophy.
Risheng Zhao   +12 more
wiley   +1 more source

Dendritic Nano‐Based Slippery Coating by Synergistic Mechanical and Electrostatic Interactions with Persistent and Exceptional Combats Thrombosis

open access: yesAdvanced Science, EarlyView.
A novel dendritic nano‐based slippery coating (DNSC), fabricated by encapsulating carboxyl silicone oil within amino dendritic silica nanoparticles and co‐embedding them in an epoxy resin matrix. The dendritic architecture enhances nanoparticle dispersion in the matrix and establishes mechanical interlock.
Shu Zhang   +12 more
wiley   +1 more source

Post‐Translational Modifications in Animal Circadian Clocks

open access: yesAdvanced Science, EarlyView.
Circadian clocks coordinate physiology with daily environmental cycles through conserved transcriptional–translational feedback loops. This review summarizes how post‐translational modifications fine‐tune clock function, highlights the evolutionary convergence of circadian timekeeping in Drosophila and mammals, and emphasizes the central of these ...
Xianhui Liu, Yong Zhang
wiley   +1 more source

Ubiquitination‐Driven Reprogramming of Proteostasis in Metastasis

open access: yesAdvanced Science, EarlyView.
The DCAF12–TRiC/CCT axis is a key regulator of metastasis in cancer. By reprogramming proteostasis to ensure efficient protein folding, it drives progression through a dual mechanism: enhancing cancer cell motility and invasiveness while concurrently activating pro‐growth and survival pathways.
Dongping Wei, Jiayan Chen, Yaping Xu
wiley   +1 more source

Home - About - Disclaimer - Privacy